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The programmed necrosis induced by TNF-a
requires the activities of the receptor-interacting
serine-threonine kinases RIP1 and RIP3 and their
interaction with the mixed lineage kinase domain-
like protein MLKL. We report the identification
of RIP1- and RIP3-containing protein complexes
that form specifically in response to necrosis induc-
tion. One component of these complexes is the
mitochondrial protein phosphatase PGAM5, which
presents as two splice variants, PGAM5L (long
form) and PGAM5S (short form). Knockdown of
either form attenuated necrosis induced by TNF-a
as well as reactive oxygen species (ROS) and
calcium ionophore, whereas knockdown of RIP3
and MLKL blocked only TNF-a-mediated necrosis.
Upon necrosis induction, PGAM5S recruited the
mitochondrial fission factor Drp1 and activated its
GTPase activity by dephosphorylating the serine
637 site of Drp1. Drp1 activation caused mitochon-
drial fragmentation, an early and obligatory step for
necrosis execution. These data defined PGAM5 as
the convergent point for multiple necrosis pathways.
INTRODUCTION
Mitochondria are now recognized as cell death executors in
addition to their more traditional roles in bioenergetics and
metabolism. During apoptosis, cytochrome c, Smac/Diablo,
Omi/HtrA2, EndoG, and AIF are released from the mitochondrial
intermembrane space and elicit biochemical reactions leading to
apoptosis (Wang and Youle, 2009). The permeability of the outer
mitochondrial membrane to these apoptogenic factors is regu-
lated by the Bcl-2 family of proteins. Antiapoptotic members of
the Bcl-2 family, such as Bcl-2, Bcl-xL, and Mcl-1, bind and
antagonize the homologous proapoptotic members of the
family, including Bax and Bak, and the ‘‘BH3-only’’ members
such as Bim, Bad, and Puma (which share homology with
Bcl-2 only at the BH3 region) (Youle and Strasser, 2008). The
current hypothesis proposes that the BH3-only proteins activate228 Cell 148, 228–243, January 20, 2012 ª2012 Elsevier Inc.Bax and Bak, leading to Bax/Bak oligomerization into protein-
permeable pores. However, direct evidence for these pores is
still lacking.
Mitochondria are interconnecting cellular organelles that
undergo dynamic changes in response to physiological and
pathological changes. True to their bacterial origin, mitochondria
undergo fission and fusion, which are processes controlled by
a group of large GTPases. In mammalian cells, mitochondrial
fusion is regulated by mitofusin-1 and -2 (MFN-1/2) and optic
atrophy 1 (OPA1), whereas mitochondrial fission is controlled
by a Dynamin-related protein 1, Drp1, and its mitochondrial
anchors Fis1 and Mff (Otera and Mihara, 2011).
Once bound to mitochondria, Drp1 assembles into spirals at
division sites around the outer mitochondrial membrane to drive
the fission process (Smirnova et al., 2001). The activity of Drp1 is
regulated by phosphorylation and dephosphorylation events.
The phosphorylation by cyclic AMP-dependent kinase (PKA) at
serine 637 site of human Drp-1 inhibits its GTPase activity and
prevents mitochondrial fission (Chang and Blackstone, 2007;
Cribbs and Strack, 2007).
Mitochondrial fragmentation has been observed during cell
death (Frank et al., 2001). Emerging evidence points to an active
role for mitochondrial fragmentation in apoptosis and necrosis.
For example, loss of Drp1 function has been shown to slow
down apoptosis and necrosis in C. elegans (Breckenridge
et al., 2008; Jagasia et al., 2005). Inhibition of Drp1 and Fis1
activity delays cell death (Frank et al., 2001; Lee et al., 2004).
Consistent with these results, boosting mitochondrial fusion by
the overexpression of MFN1 and MFN2 inhibits apoptosis
(Sugioka et al., 2004), and the downregulation of OPA1 induces
the spontaneous apoptosis (Olichon et al., 2003).
The receptor-interacting kinase RIP3 is a critical signaling
component for the cellular necrotic response to the TNF-a family
of cytokines (Declercq et al., 2009). This form of necrotic cell
death (also known as necroptosis) has been implicated in devel-
opment, tissue damage during acute pancreatitis, retinal detach-
ment, and antiviral immunity (Cho et al., 2009b; He et al., 2009;
Kaiser et al., 2011; Oberst et al., 2011; Trichonas et al., 2010;
Upton et al., 2010). The necrosis pathway downstream of RIP3
remains largely unknown, although ROS generation, calcium
overload, and the opening of the mitochondrial permeability
transition pore have been implicated (Vanlangenakker et al.,
2008).
Taking advantage of a chemical compound, necrosulfona-
mide (Sun et al., 2011 [this issue of Cell]), which specifically
inhibits TNF-a-mediated necrosis downstream of RIP3 activa-
tion and a cell line harboring a tagged version of functional
RIP3 under the control of an inducible promoter, we identified
multiprotein complexes that specifically formed after necrosis
induction. Our results show that one of the components is the
mitochondrial phosphoglycerate mutase/protein phosphatase
PGAM5, which functions as a convergent point for multiple
necrotic death pathways.
RESULTS
RIP3 Overexpression Augments TNF-a-Induced
Necrosis
To characterize the role of RIP3 in necrosis, we generated aHeLa
stable cell line that harbored a doxycycline (Dox)-inducible
expression construct containing RIP3 fused to a 3xFlag tag
and an HA tag at its N terminus. HeLa cells normally do not
express RIP3. Addition of Dox to the culture media induced
expression of RIP3 that was more than 20-fold higher than the
basal level (leaky) expression of RIP3 transgene, which was
about four times the level of endogenous RIP3 in human colon
cancer HT-29 cells (Figure 1A). Before Dox addition, the basal
expression of RIP3 transgene in HeLa cells made the cells
behave similarly to HT-29 cells. The cells underwent necrosis
when treated with the combination of TNF-a, the Smac mimetic
and z-VAD-fmk, but remained alive when treated with TNF-a
alone or TNF-a plus either Smac mimetic or z-VAD-fmk (Fig-
ure 1B; He et al., 2009). The necrosis was inhibited by an allo-
steric RIP1 kinase inhibitor necrostatin-1 and the mixed lineage
kinase-like (MLKL) protein inhibitor necrosulfonamide (Degterev
et al., 2008; Sun et al., 2011). With the addition of Dox, the cells
underwent necrosis in response to TNF-a alone as well as to
TNF-a plus either z-VAD-fmk and/or the Smac mimetic (Fig-
ure 1B). This observation is consistent with the previous findings
that higher levels of RIP3 may cause cells to undergo necrosis in
response to TNF-a alone, bypassing the requirement of z-VAD-
fmk and Smac mimetic (He et al., 2009; Trichonas et al., 2010).
Moreover, necrosis also proceeded faster upon Dox addition
(Figure S1A available online).
Interestingly, the Dox-induced higher level of RIP3 expression
abolished the ability of necrostatin-1 to efficiently block necrosis
in these cells, although knockdown of its target RIP1 still attenu-
ated necrosis (Figures 1B and S1B). It is likely that with higher
level of RIP3, cells were able to overcome the allosteric inhibition
of necrostatin-1 on RIP1. In contrast, necrosulfonamide still effi-
ciently prevented necrosis under the same conditions (Fig-
ure 1B). Consistently, knockdown of MLKL in the Dox-treated
HeLa cells also blocked necrosis (Figure S1B).
Necrosulfonamide Blocks Mitochondrial Fragmentation
Associated with Necrosis
To monitor the morphological changes associated with TNF-
a-induced necrosis in detail, we transiently expressed RFP-
ANT1, a mitochondrial marker, and YFP-HMGB1, a nuclear
marker, into the Dox-induced, RIP3-expressing HeLa cells.
These cells were treated by the combination of TNF-a, Smacmimetic, and zVAD-fmk and analyzed with a spinning-disk
confocal microscope. As shown in Figure 1C, the shape of nuclei
and tubular mitochondria was normal before the treatment. After
120 min of treatment, the mitochondria became fragmented into
small dots scattered throughout the cell, whereas the nuclear
and cytoplasmicmembranes were intact. At 360min, the nuclear
membrane broke down and the YFP signal dispersed into the
cytosol, while the mitochondria formed clumps. By 580 min,
the YFP signal eventually dissipated, indicating the breakdown
of the plasma membrane.
Consistent with the observation that necrostatin-1 failed to
block necrosis when RIP3 was overexpressed (Figure 1B), the
addition of necrostatin-1 did not prevent the mitochondrial frag-
mentation and clustering as visualized by immunofluorescent
staining of Tom20, another mitochondrial marker (Figure 1D).
In contrast, in the presence of necrosulfonamide, the tubular
mitochondrial morphology remained normal (Figure 1D). Consis-
tently, knockdown of MLKL, the cellular target of necrosulfona-
mide, also prevented the mitochondrial morphological changes
under necrosis-inducing conditions, whereas a control luciferase
knockdown did not (Figure 1E).
RIP3 Forms a Protein Complex with PGAM5 upon
Necrosis Induction
To search for RIP3 substrates that function in the necrosis
pathway, we immunoprecipitated the Flag-tagged RIP3 from
HeLa cells treated with the vehicle DMSO or necrosis-inducing
agents (TNF-a/Smac mimetic/Z-VAD). We then performed an
in vitro kinase assay by incubating g-32P ATP with the immune
complex and analyzed the protein phosphorylation by SDS-
PAGE and autoradiography. As shown in Figure 2A, a phos-
phate-labeled protein at the expected position of RIP3 was
detected before necrosis induction, indicating that there is
a basal level of RIP3 activity in living cells. After necrosis induc-
tion, two additional bands that migrated slightly above the
55 and 35 kDa markers also appeared (Figure 2A). The upper
band was at the expected position of MLKL, a newly discovered
substrate of RIP3 (Sun et al., 2011).
In order to get the molecular identity of the lower band, we
first fractionated cell extracts by centrifugation. The RIP1/RIP3
complexwas found tobemoreprominent in theheavymembrane
fraction (pellet fraction after centrifugation at 15,000 3 g) after
necrosis induction, and the complex accumulated in the pres-
ence of necrosulfonamide (Figure 2B). We then immune-purified
the RIP3-containing complex from the p15 fraction and resolved
the accumulated RIP3 immunocomplex using a gradient SDS-
PAGE gel. We subsequently identified all of the associated
proteins by silver staining followed by mass spectrometry. As
indicated in Figure 2C, the protein bands that specifically associ-
ated with RIP3 during necrosis were RIP1, RIP3, MLKL, and
PGAM5, a mitochondrial phosphoglycerate mutase that uses
alternative catalytic activity to function as a Ser/Thr phosphatase
(Takeda et al., 2009). The major PGAM5 protein band ran at the
same position as the 35 kDa phospho-protein band identified
in the in vitro kinase assay, suggesting that PGAM5 might be
another substrate of RIP1/RIP3 necrosome. PGAM5 has been
shown to localize to the outer membrane of mitochondria with
its C terminus facing the cytoplasm (Lo and Hannink, 2008).Cell 148, 228–243, January 20, 2012 ª2012 Elsevier Inc. 229
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Figure 1. Necrostatin-1 and Necrosulfonamide Block TNF-a-Induced Necrosis at Different Steps
(A) Western blotting measurement of RIP3 levels before and after Dox-induced expression of stably transfected HA-3xFlag tagged RIP3 transgene in a HeLa cell
line (HeLa/TO-Rip3).
(B) HeLa/TO-Rip3 cells with or without Dox induction were treated with the indicated necrosis-inducing agent(s) for 24 hr. Cell viability was determined using the
CellTiter-Glo assay. TNF-a (20 ng/ml), 100 nM Smac mimetic, 20 mM Z-VAD, 10 mM necrostatin-1, and 2 mM necrosulfonamide were used. The same
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To verify the specific association between RIP3 and PGAM5,
we probed the RIP3 immunocomplex using an anti-PGAM5 anti-
body. Western blotting analysis of RIP1 and MLKL was also per-
formed as controls. As shown in Figure 2D, similar to RIP1, the
PGAM5 signal appeared in the complex only under necrosis-
inducing conditions and increased in the presence of necrosulfo-
namide (lanes 1–3). In contrast, a kinase-dead form of RIP3
(K50A) failed to precipitate PGAM5 even though it still bound
to RIP1 as previously observed (He et al., 2009). Similarly, the
kinase-dead RIP3 also failed to interact with MLKL (Sun et al.,
2011). The lower band of PGAM5 detected by western blotting
might be a proteolytic or alternatively spliced form of PGAM5.
The necrosis-specific association between PGAM5 and RIP1/
RIP3 was further verified by a reciprocal pull-down experiment
using an anti-PGAM5 antibody (Figure 2E).
To test if the association of PGAM5 with RIP1/RIP3 regulates
the phosphatase activity of PGAM5, we immunoprecipitated
RIP3 under normal or necrotic conditions and incubated the
pellets with purified recombinant PGAM5 in an in vitro kinase
and a phosphatase assay. As shown in Figure 2F, the recombi-
nant PGAM5 was phosphorylated by the RIP3 complex under
necrotic conditions. Interestingly, the phosphatase activity of
recombinant PGAM5 showed significant increase after incuba-
tion with the RIP3 complex isolated under the necrotic condi-
tions (Figure 2G).
Both Splice Variants of PGAM5 Are Required
for Necrosis Execution
To verify the role of PGAM5 in necrosis execution, we performed
siRNA knockdown of PGAM5 using two independent siRNA
oligos targeting the coding region of PGAM5. Compared to
a control luciferase siRNA oligo, knockdown of PGAM5 in the
RIP3-expressing HeLa cells or HT-29 cells attenuated necrosis
about 2-fold, and the efficiency of knockdown correlated with
the degree of necrosis rescue (Figures 3A, 3B, and 3D). To further
increase the knockdownefficiency,wealsogenerated twoHT-29
cell linesstably expressingeachshRNAwith the samesequences
as the two siRNA oligos used for the transient knockdown. The
PGAM5 was knocked down to a much lower level in these cells
and nearly twice as many cells were rescued from necrosis
compared to transient knockdown using siRNA oligos (Figures
3C and 3D). To rule out the off-target effects of these shRNAs,
we attempted to rescue the PGAM5 knockdown by expressing
an shRNA-resistant cDNA of PGAM5 (Figures 3C and 3D, last
lane). To our surprise, the cells were still resistant to necrosis,
although the shRNA-resistant cDNA of PGAM5 generated more
PGAM5 protein than the endogenous PGAM5 (Figure 3D). The
ectopically expressed PGAM5 should be functional since thisconcentrations were used in all experiments unless otherwise stated. The CellT
experiment. Data are represented as the mean ± STDEV of duplicates. T, TNF-a
(C) Sequential morphological changes during necrosis. HeLa/TO-Rip3 cells were
TSZ was added and live cell imaging was recorded. Bar equals 10 mm. For all th
otherwise stated.
(D) HeLa/TO-Rip3 cells were treated as indicated for 6 hr, and immunostainin
selected.
(E) HeLa/TO-Rip3 cells were transfected with an siRNA against luciferase (luc) or
was preformed using an anti-Tom20 antibody.
See also Figure S1.form of PGAM5 in host cells accelerated necrosis and rendered
them resistant to antinecrosis compounds (Figures S2A–S2C).
One possible explanation for such a result was that the
shRNA-resistant cDNAused in the rescue experiment expressed
only one of the two splice variants of PGAM5, whereas the
shRNA targeted the common region of both isoforms. The
inability of this isoform of PGAM5 to rescue shRNA knockdown
suggested that both forms of PGAM5 participated in necrosis
execution. To investigate such a possibility, we had to find
a way to unambiguously distinguish these two spliced forms.
The alternative splicing made a truncation at amino acid
residue 239 of the long form of PGAM5, PGAM5L, and an
addition of 16 hydrophobic amino acid residues at the C
terminus (Figure 3E; Lo and Hannink, 2006). These changes
potentially rendered the short form of PGAM5, PGAM5S, more
hydrophobic than PGAM5L. Therefore, we suspected that the
extraction buffer we used for PGAM5L (containing 1% Triton
X-100) did not extract PGAM5S. Since PGAM5L was often
proteolyzed into several small fragments that overlapped in
size with PGAM5S (Figure 2C), we had to individually engineer
a Myc-tag into PGAM5S and PGAM5L to specifically study their
distributions (Figure 3F). Indeed, we found that PGAM5Swas not
present in the Triton X-100 extractable fraction. We subse-
quently lysed the Triton X-100 insoluble pellet with a buffer con-
taining 1% SDS and then diluted the 1% SDS-extracted soluble
fraction into 0.1% SDS for the coimmunoprecipitation studies.
As shown in Figure 3F, PGAM5S was only present in the 1%
SDS-soluble fraction. The ability to specifically probe PGAM5L
and PGAM5S allowed us to dissect the roles of these two splice
forms in necrosis.
We designed siRNA oligos targeting the 30-untranslated region
of PGAM5 that specifically knocked down only one form of
PGAM5. As shown in Figures 3E, 3G, and 3H, all of these siRNA
oligos attenuated necrosis to a degree that correlated with the
respective efficacy for PGAM5S or PGAM5L knockdown, con-
firming our hypothesis.
We then tried to rescue necrosis in shRNA-expressing HT-29
cells with double expression of shRNA-resistant PGAM5L and
PGAM5S. The expression of both spliced forms of PGAM5
significantly rescued necrosis compared to either form alone
(Figures 3I and S2).
Necrosulfonamide Blocks the Interaction between
PGAM5S and RIP3
We next analyzed the specific interaction between RIP3 and
PGAM5S. As shown in Figure 4A, RIP1, RIP3 and PGAM5L
were coprecipitated with the anti-Myc (PGAM5S) antibody under
necrotic conditions. Interestingly, necrosulfonamide completelyiter-Glo assay was used to determine the cell viability in all the subsequent
; S, Smac mimetic; Z, Z-VAD; Nec-1, necrostatin-1; NSA, necrosulfonamide.
transfected with RFP-ANT1 and YFP-HMGB1 expression plasmids. At 24 hr,
e subsequent experiments, Dox was added to the HeLa/TO-Rip3 cells unless
g was preformed using an anti-Tom20 antibody. Representative fields were
MLKL. After 48 hr, the cells were treated with TSZ for 6 hr, and immunostaining
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Figure 2. Mitochondrial Phosphatase PGAM5L Is a Kinase Substrate of RIP1/RIP3
(A) HeLa/TO-Rip3 cells were treated with DMSO or TSZ for 6 hr. Whole-cell extract was immunoprecipitated with anti-Flag agarose. The beads were then
incubated with g-32P-ATP before eluted with SDS sample buffer and subjected to SDS-PAGE followed by autoradiography.
(B) S15 and P15 fractions were extracted from HeLa/TO-Rip3 cells and subjected to anti-Flag immunoprecipitation. The immunoprecipitant was eluted with
33 Flag peptide and analyzed by western blotting with indicated antibodies.
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blocked the interaction between PGAM5S and RIP1/RIP3. Since
necrosulfonamide did not affect PGAM5L interaction with RIP1/
RIP3 (Figure 2D), we concluded that PGAM5S is the downstream
effector of RIP1/RIP3/MLKL/PGAM5L complex and necrosulfo-
namide blocks necrosis by preventing PGAM5S from associa-
tion with this complex.
The Phosphorylation of PGAM5L and PGAM5S
during Necrosis Is Differentially Regulated
by Necrosulfonamide
The association of both isoforms of PGAM5 with the RIP1/RIP3
kinase complexduringnecrosis suggested thatPGAM5L/Smight
be the kinase substrates. To directly analyze the phosphorylation
eventsof theseproteins,wesubjected the twoprotein-containing
fractions to two-dimensional electrophoresis followedbywestern
blot analysis. We probed the filter with anti-Flag (RIP3) antibody
as a positive control because RIP3 is a known phosphoprotein
and its upward shifts during necrosis could be readily shifted
down by the phosphatase treatment (Figure S3). As shown in
Figure 4B, an upward shift of molecular weight measured by
SDS-PAGE and a leftward shift of negative charge measured by
isoelectric focusing electrophoresis were observed for RIP3 after
necrosis induction. Consistent with the previous notion that ne-
crosulfonamide prevents necrosis downstream of RIP3, the
presence of necrosulfonamide augmented these shifts of RIP3.
These necrosis-associated changes were abolished by pretreat-
ment of the extracts with l-phosphatase, confirming that the
changes were caused by phosphorylation of RIP3. When the
same analysis was performed for PGAM5L and PGAM5S, both
isoforms exhibited necrosis-induced phosphorylation similar to
RIP3 (Figures 4C and 4D). Notably, the phosphorylation of
PGAM5L was not affected by necrosulfonamide (Figure 4C,
lower), whereas the phosphorylation of PGAM5S was totally
abolished by the compound (Figure 4D, lower).
Because necrosulfonamide specifically targets MLKL (Sun
et al., 2011), we analyzed the phosphorylation status of PGAM5S
after MLKL knockdown. As shown in Figure 4E, MLKL knock-
down also abolished PGAM5S phosphorylation similar to ne-
crosulfonamide treatment. These results are consistent with
a model that MLKL mediates the proper targeting of RIP1/RIP3
necrosome to its downstream effector PGAM5S.
Phosphorylation-Dependent Distribution of RIP1/RIP3
Complex in the SDS-Soluble Fraction
The specific distribution of PGAM5S in the SDS-soluble fraction
indicated that that these locations might be the sites of mito-(C) HeLa/TO-RIP3 cells were treated as indicated for 6 hr. The P15 fraction wa
separated on a 4%–12% gradient gel and detected by silver staining. The indica
(D) HeLa/TO-Rip3 or HeLa/TO-Rip3-K50A (a similarly generated cell line expressin
the P15 fraction was used for anti-Flag immunoprecipitation. The immunoprecipita
indicated antibodies.
(E) HeLa/TO-Rip3 cells were treated as indicated for 6 hr. The P15 fraction wa
complexes were analyzed by western blotting using the indicated antibodies.
(F) HeLa/TO-Rip3 cells were treated as indicated for 6 hr. Whole-cell extracts we
analyzed by western blotting for RIP3 (Flag) or RIP1, or incubated with g-32P-
PGAM5L was analyzed by SDS-PAGE followed by autoradiography (top).
(G) An in vitro kinase assay for PGAM5L was performed as in (F) with cold ATP
Procedures. *p < 0.05.chondrial fragmentation, which is an early event during necrosis
(Figure 1C). We therefore analyzed the 1% SDS soluble fraction
for the presence of RIP1/RIP3 and Drp1, which controls mito-
chondrial fission, a process that could lead to mitochondrial
fragmentation. As shown in Figure 5A, RIP1 and RIP3 were
shifted upward after necrosis induction, and the upward shifts
accumulated in the presence of necrosulfonamide in the
whole-cell extracts prepared by Triton X-100 extraction (lanes
1–3). The upward shifts were not observed in cells expressing
the kinase-dead form of RIP3 (lanes 4–6). Interestingly, only the
upward-shifted RIP1 andRIP3 ended up in the SDS-soluble frac-
tions after necrosis induction (lanes 8 and 9). The proteolytic
form of PGAM5L and Drp1 also appeared in the SDS-soluble
fraction after necrosis induction. Upon necrosulfonamide
treatment, PGAM5L and Drp1 were no longer detected in the
SDS-soluble fraction, whereas RIP1 and RIP3 were not much
affected. These results again confirmed that necrosulfonamide
worked downstream of RIP1/RIP3 activation (lanes 8 and 9).
Drp1 Activation during Necrosis
The specific appearance of Drp1 in the 1% SDS-soluble fraction
during necrosis suggested that Drp1 might function in the
necrotic process. We further explored this possibility by moni-
toring its distribution during necrosis by immunostaining. As
shown in Figure 5B, Drp1 was evenly distributed in the cytosol
and partially colocalized with tubular mitochondria in DMSO-
treated cells (top). After necrosis induction, mitochondria formed
clumps around nucleus and Drp1 was greatly enriched on mito-
chondria (bottom).
Drp1 dephosphorylation at amino acid residue serine 637
indicates Drp1 activation (Chang and Blackstone, 2007; Cribbs
and Strack, 2007). A phospho-specific antibody recognized
the phosphorylation of this site (Figure 5C, lane 1). After
necrosis induction, the phosphorylation signal was lost, whereas
necrosulfonamide blocked the dephosphorylation of S637
during necrosis (lanes 2 and 3). The total amount of Drp1 did
not change significantly during necrosis (Figure 5C). In addition
to S637 dephosphorylation, activated Drp1 formed dimers
through disulfide linkage of monomers (Cho et al., 2009a).
Necrosis induction also increased dimer formation of Drp1,
which was attenuated by necrosulfonamide (Figure 5D).
To directly demonstrate Drp1 activation during necrosis, we
immunopurified Drp1 from control and necrotic cells and mea-
sured its GTPase activity. As shown in Figure 5E, the GTPase
activity of Drp1 was significantly increased during necrosis,
which was inhibited by necrosulfonamide.s used for anti-Flag and anti-HA tandem pull-downs. The final eluates were
ted protein bands were identified by mass spectrometry.
g a kinase-dead form K50A of RIP3) cells were treated as indicated for 6 hr and
nt was eluted with 33 Flag peptide and analyzed by western blotting using the
s used for immunoprecipitation with an anti-PGAM5 antibody. The immune
re used for anti-Flag immunoprecipitation. The immune complexes were either
ATP and 100 ng of recombinant His-PGAM5L (88–289). The phosphorylated
. The phosphatase activity was then measured as described in Experimental
Cell 148, 228–243, January 20, 2012 ª2012 Elsevier Inc. 233
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Figure 3. Both PGAM5L and PGAM5S Are Required for TNF-a-Induced Necrosis
(A and B) HeLa/TO-Rip3 cells (A) or HT-29 cells (B) were transfected with siRNAs against luciferase (luc) or PGAM5 (P1 and P2) for three rounds. Cell viability was
determined after 24 hr of TSZ treatment.
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PGAM5S Recruits and Activates Drp1 on Mitochondria
To test whether the activation of Drp1 during necrosis requires
PGAM5, we first tested the possibility that PGAM5S directly
recruited Drp1 to mitochondria. To this end, we ectopically
expressed Myc-tagged PGAM5L and PGAM5S separately in
the RIP3-expressing HeLa cells and immunoprecipitated them
with an anti-Myc antibody. The immune complexes were subse-
quently probed with antibodies against Myc and Drp1. As shown
in Figure 5F, Drp1 was specifically coprecipitated with PGAM5S
but not PGAM5L although similar amount of each was precipi-
tated by the anti-Myc antibody.
To directly demonstrate that PGAM5 dephosphorylated Drp1
and activated its GTPase activity, we incubated purified wild-
type recombinant PGAM5L or a phosphatase dead (H105A) form
with the immunopurified Drp1. PGAM5L was used as a surrogate
for PGAM5S because recombinant PGAM5S was not soluble in
the assay buffer and the enzymatic portions of these two proteins
are identical. As shown in Figures 5G and 5H, respectively, the
wild-type PGAM5L dephosphorylated Drp1 at serine 637 and
dramatically increased its GTPase activity, whereas the phospha-
tase-dead form of PGAM5L did not cause these changes.
Knockdown of PGAM5S Attenuates Drp1 Activation
To further characterize the specific role of PGAM5S in activating
Drp1, we measured Drp1 distribution and activation markers in
cells stably expressing an shRNA targeting the unique
30-untranslated region of PGAM5S (Figure 3E). Knockdown of
PGAM5S prevented necrosis and necrosis-associated mito-
chondrial fragmentation and aggregation (Figures 6A and 6B).
The preventative effect of PGAM5S knockdown was not caused
by an off-target effect of the shRNA because expressing the
shRNA-resistant wild-type PGAM5S but not the phosphatase-
dead (H105A) form rescued necrosis in these cells (Figures 6A
and S4). In these PGAM5S knockdown cells, appearance of
proteolytic form of PGAM5L and Drp1 in the 1% SDS-soluble
fraction during necrosis was also eliminated (Figure 6C, compare
lanes 8 and 11). Consistently, Drp1 dephosphorylation at S637
and Drp1 dimerization, the two markers for its activation, were
significantly attenuated in these cells (Figures 6D and 6E).
Drp1 Is Required for Necrosis Induction
The necrosis-dependent association of Drp1 with PGAM5S and
Drp1 activation suggested that Drp1 might be required for(C) HT-29 stable cell lines expressing P1 or P2 shRNAwere generated as describe
targeting site was stably expressed in the shPGAM5-P2 cells to generate the PGA
(D) Western blotting was used to measure the knockdown efficiency in (B) and (C
(E) Schematic representation of the siRNAs used for PGAM5L and PGAM5S.
(F) PGAM5S is localized in an SDS-soluble domain. HeLa cells were transfected
(WCEs), the pellet was further extracted with 1% SDS. Western blotting was per
(G) HT-29 cells were transfected with three rounds of siRNA oligos targeting regi
determined after 24 hr of TSZ treatment.
(H) Comparing the knockdown efficiency of isoform specific siRNA oligos used in
and WCE was used for western blotting. For PGAM5S, an expression plasm
cotransfected with the siRNAs into HeLa cells. After 72 hr, the WCE was discard
blotting was performed with anti-PGAM5 and anti-b-actin antibodies.
(I) Myc-PGAM5S construct was stably expressed in the shPGAM5-P2 cells to gene
the PGAM5L-rescue cells to generate PGAM5L-5S double rescue cell line. Cell via
mean ± STDEV of duplicates.
See also Figure S2.necrosis execution. To further demonstrate this point, we treated
HT-29 cells and the RIP3-expressing HeLa cells with a Drp1
inhibitor mdivi-1 (Cassidy-Stone et al., 2008). Necrosis was
attenuated in both cell lines with increasing concentrations of
mdivi-1 (Figure 6F). Additionally, knockdown Drp1 in both cell
lines blocked necrosis (Figure 6G).
These data suggested that PGAM5S is a central necrosis
mediator. It connects the upstream necrosome with Drp1 during
necrosis (Figure 6H and see more in the Discussion section).
PGAM5 Functions in Multiple Necrotic Pathways
Thecell lineswith stable knockdownofPGAM5Land/orPGAM5S
provided us with an opportunity to study their roles in cell death
induced by other agents. For example, t-butyl hydroxide (TBH),
a ROS generator, also induced mitochondrial fragmentation
and clustering around nuclei at a concentration of 100 mM
(Figure 7A). The pan-caspase inhibitor zVAD-fmk augmented
cell death, indicating that cell death was mediated by necrosis
not apoptosis (Figure 7B). As expected, a ROS scavenger,
N-acetyl-L-cysteine (NAC), attenuated cell death to some extent
(Figure 7B). Interestingly, the majority of cells expressing the
shRNA against PGAM5 (both forms) survived 100 mM TBH treat-
ment (Figure 7C). Approximately 30%of these cells also survived
5mMhydrogen peroxide treatment, a harsh condition that wiped
out all the parental HT-29 cells (Figure 7D). In contrast, RIP3
knockdown did not prevent TBH- or H2O2-induced cell death.
Another common inducer of necrotic death is a calcium iono-
phore that produces transient calcium flashes in cells. Treatment
of HT-29 cells with the calcium ionophore A23187 and the
caspase inhibitor z-VAD-fmk caused more than 80% of treated
cells to die (Figure 7E). Knockdown of RIP3 did not affect this
form of cell death. However, 50%–60%of HT-29 cells that stably
expressed shRNA against PGAM5 survived the treatment of
A23187 and z-VAD-fmk.
These data suggested that PGAM5 might be the converging
point of multiple necrosis pathways. The extrinsic signal such
as TNF-a activates necrosis by engaging the RIP1/RIP3/MLKL
necrosome pathway leading to the activation of PGAM5 and
Drp1. The intrinsic necrosis-inducing signals such as TBH and
A23187 might be able to activate PGAM5 and Drp1 independent
of RIP1/RIP3/MLKL.
To further test this hypothesis, we knocked down RIP1,
RIP3, MLKL, Drp1, PGAM5L, and PGAM5S before treatingd in Experimental Procedures. Myc-PGAM5L with silent mutation of the shRNA
M5L-rescue cell line. Cell viability was determined after 24 hr of TSZ treatment.
).
with a plasmid expressing Myc-PGAM5S. After isolating whole-cell extracts
formed with anti-Myc, anti-PGAM5, and antivimentin antibodies.
ons specific for either PGAM5L or PGAM5S as indicated, and cell viability was
(G). For PGAM5L, HeLa cells were transfected with the siRNAs for two rounds
id including the coding region and 30-untranslated region of PGAM5S was
ed, and the cell pellet was directly boiled in 1 3 SDS loading buffer. Western
rate the PGAM5S-rescue cell line. The same construct was stably expressed in
bility was determined after 24 hr of TSZ treatment. Data are represented as the
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See also Figure S3.the cells with these intrinsic necrosis stimuli. As shown in
Figures 7F–7H, knockdown of Drp1, PGAM5L, and PGAM5S,
either individually or together, attenuated cell death induced236 Cell 148, 228–243, January 20, 2012 ª2012 Elsevier Inc.by TBH, H2O2, and A23187. In contrast, knockdown of RIP1,
RIP3, and MLKL did not affect cell death induced by these
agents.
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Figure 5. Drp1 Is Activated by PGAM5 upon Necrosis Induction
(A) Cells were treated as indicated for 6 hr. WCE and SDS-sup were isolated as described in Figure 3F and subjected to western blotting analysis with indicated
antibodies.
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Similar results were obtained in mouse embryonic fibroblast
cells, suggesting that the same mechanism applies to other
mammalian systems (Figure S5).
Staurosporine-induced apoptotic death was not affected by
PGAM5 knockdown, indicating that PGAM5 might be specifi-
cally required for necrotic death (Figure S6).
DISCUSSION
PGAM5 at the Convergent Point of Extrinsic
and Intrinsic Pathways of Necrosis
Our experimental data indicate that the two splice variants of the
mitochondrial protein phosphatase PGAM5 are at the conver-
gent point of multiple necrosis pathways. Similar to apoptosis
that is initiated extrinsically by ligands for death receptors and
intrinsically by BH3-only proteins, necrosis can also be triggered
by both extrinsic and intrinsic signals. The extrinsic necrosis
pathway relies on necrosome components consisting of the
kinases RIP1, RIP3, and mixed lineage kinase domain-like
protein MLKL (He et al., 2009; Holler et al., 2000; Sun et al.,
2011). Downstream of the necrosome are two isoforms of
PGAM5, which specifically associate with the necrosome after
necrosis induction, resulting in PGAM5 phosphorylation and
activation.
In contrast to extrinsic signals, the kinases RIP1 and RIP3, as
well as MLKL, are not involved in the forms of necrosis that are
induced by ROS generators or calcium ionophore (Figure 7).
These signaling proteins are specific for the extrinsic necrosis
(necrosome) pathway. However, both isoforms of PGAM5 func-
tion in the intrinsic necrosis pathway, based on the evidence that
PGAM5 knockdown attenuates ROS- and calcium ionophore-
induced necrotic death.
Activation Model for PGAM5L and PGAM5S
during Necrosis
We propose that PGAM5L and PGAM5S are activated in a three-
stage model in the extrinsic necrosis pathway (Figure 6H). The
first stage is the formation of necrosome that is initiated by the
activation of TNFR and the formation of the RIP1-containing
signaling complex (complex I), which primarily functions to
activate NF-kB (Micheau and Tschopp, 2003). The conversion
of the membrane-associated complex I to the cytoplasmic(B) HeLa/TO-Rip3 cells were treated with DMSO (top) or TSZ (bottom) for 6 hr. Imm
(Green) antibodies. Bar equals 10 mm.
(C) HeLa/TO-Rip3 cells were treated as indicated for 6 hr. Whole-cell extracts w
complexes were analyzed by western blotting with a mouse anti-Drp1 antibody.
(D) HeLa/TO-Rip3 cells were treated as indicated for 6 hr. Whole-cell extracts wer
with an anti-Drp1 antibody.
(E) HeLa/TO-Rip3 cells were treated as indicated for 6 hr. GTPase activity of the i
*p < 0.05.
(F) HeLa/TO-Rip3 cells were transfected with a plasmid expressing Myc-PGAM5L
for anti-Myc immunoprecipitation. For Myc-PGAM5S expressing cells, the pellet a
times with lysis buffer and thenmixed withWCE for immunoprecipitation with anti-
antibodies against Myc (for PGAM5) and Drp1.
(G) Immunoprecipitated Drp1 was incubated with 3 mg of recombinant His-PGAM5
western blotting with anti-Drp1 and anti-Drp1-p637 antibodies. The intensity of th
machine. The relative intensity was labeled under each lane.
(H) Drp1 immunoprecipitation and incubation with recombinant PGAM5L were p
GTPase activity assay. *p < 0.05.
238 Cell 148, 228–243, January 20, 2012 ª2012 Elsevier Inc.complex II is mediated by the following: deubiquitylation of
RIP1 by the deubiquitin enzyme CYLD; cIAPI/II degradation,
which is triggered by Smac or Smac mimetics (Wang et al.,
2008); and the binding of RIP3 and MLKL to the RIP1-containing
complex (He et al., 2009; Sun et al., 2011). The successful forma-
tion of this complex requires the inhibition of caspase-8, which is
also recruited to the RIP1-containing complex for activation
(Wang et al., 2008).
The second stage of this necrosis pathway is the binding of
PGAM5L to the necrosome. Notably, the binding of PGAM5L is
not affected by the presence of the necrosis inhibitor necrosulfo-
namide. Necrosulfonamide arrests the necrosis-inducing protein
signaling complex at this step, allowing the stable association of
PGAM5L with the necrosome, which manifest as discrete cyto-
solic punctae (Sun et al., 2011). At this stage, the early RIP1
associated proteins including TRADD, FADD, Caspase-8, and
Flip are no longer stoichiometric components of the complex
(Figure 2C). The complex might loosely associates with mito-
chondria at this point, although the stoichiometry may not allow
complete colocalization.
The third step is the association of this complex with PGAM5S.
The compound necrosulfonamide blocks the binding of
PGAM5S to the RIP1/RIP3/MLKL/PGAM5L complex. Consis-
tently, the necrosis-associated phosphorylation of PGAM5S
does not occur in the presence of necrosulfonamide, whereas
phosphorylation of PGAM5L is not affected (Figure 4). PGAM5S
is normally located in a more hydrophobic environment on mito-
chondria and becomes associated with the upstream necrosis-
inducing complex probably through interactions with RIP3
and/or PGAM5L, resulting in the activation of PGAM5S by phos-
phorylation. Along this process, PGAM5Lmay also become pro-
teolyzed before binding to PGAM5S.
The binding of the necrosome to PGAM5Smarks its transloca-
tion to a more hydrophobic environment or the formation of
larger aggregates that are soluble in 1% SDS but not 1% Triton
X-100. The candidates for these hydrophobic locations are the
constriction sites for mitochondrial fission where Drp1 forms
27 nm tubules (Yoon et al., 2001).
Drp1 Is Part of Necrosis Execution
Consistent with our model, Drp1 was activated during TNF-
induced necrosis, whichwasmeasured by its dephosphorylationunostaining was performed with rabbit anti-Tom20 (Red) andmouse anti-Drp1
ere used for immunoprecipitation with anti-Drp1-p637 antibody. The immune
e subjected to a nonreducing SDS-PAGE followed by western blotting analysis
mmunopurified Drp1 was measured as described in Experimental Procedures.
or Myc-PGAM5S. For Myc-PGAM5L expressing cells, WCE was directly used
fter WCE was further extracted with 1% SDS. The SDS-extract was diluted ten
Myc agarose. The immune complexes were analyzed bywestern blotting using
L (22–289) or H105Amutant at 30C for 6 hr. The beads were then subjected to
e western blotting signal was quantified with a Kodak Image Station 4000R Pro
erformed similarly as described in (G). The beads were then subjected to the
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Figure 6. Drp1 Is Required for TNF-a-Induced Necrosis
(A) A stable cell line expressing shRNA against PGAM5S was generated in the HeLa/TO-Rip3 cells. Stable rescue cell lines expressing Myc-PGAM5S or Myc-
PGAM5S-H105A were established in the sh5S-3UTR cells. Cell viability was determined after 24 hr of TSZ treatment (left). Knockdown efficiency was assayed
using quantitative RT-PCR (right).
(B) The cells were treated with TSZ for 6 hr and immunostaining was performed with anti-Tom20 antibody. Bar equals 10 mm.
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at serine 637, dimer formation, and elevated GTPase activity.
All of these biochemical features are blocked by the necrosis
inhibitor necrosulfonamide, indicating that the activation of
Drp1 is a downstream event. These necrosis-associated
changes are likely to be directly caused by PGAM5S. Because
PGAM5S is hydrophobic and not compatible with biochemical
assays in vitro, it is difficult to experimentally test the ability of
PGAM5S to directly dephosphorylate and activate Drp1. Never-
theless, purified recombinant PGAM5L dephosphorylated and
activated Drp1 (Figure 5). Because both isoforms of PGAM5
may eventually function in one large complex at the constriction
sites of mitochondrial fission, Drp1 may be activated in situ at
these sites.
Drp1-mediated mitochondrial fragmentation seems to be
a common required step for apoptosis and necrosis. For
apoptosis, mitochondrial fragmentation may be involved in mito-
chondrial outer membrane permeabilization, leading to cyto-
chrome c release and caspase activation. During necrosis,
mitochondria fragment and subsequently cluster around nuclei
before nuclear and cytoplasmic membrane breakdown, the
terminal stage of necrosis (Figure 1C). Yet, cytochrome c is
not released during TNF-induced necrosis (Temkin et al.,
2006), suggesting that the downstream event following mito-
chondrial fragmentation could be different between apoptosis
and necrosis.
Another interesting feature of PGAM5L is that it is a substrate
for Keap-1, a thiol-reactive sensor for ROS, and a substrate
adaptor protein for a Cul3-dependent ubiquitin ligase complex
(Lo and Hannink, 2008). It is conceivable that the PGAM5L/
Keap-1 complex might be an effector for ROS-induced necrosis.
However, the detailed mechanism requires further study. The
link between calcium ionophore and PGAM5 is also unclear,
but the molecular reagents described here should allow us to
explore this topic in the future. The importance of these studies
is highlighted by the finding that the loss of PGAM5 homolog in
Drosophila suppresses the effects of inactivation of early Parkin-
son-responsible gene product PINK1, including mitochondrial
degeneration, motor defects, and the shortened life span (Imai
et al., 2010).
How mitochondrial fragmentation mediated by Drp1 causes
necrosis is still not clear. Mitochondrial fragmentation may
reduce energy production, increase ROS generation, or activate
yet to be defined downstream necrosis execution steps. There-
fore, the challenge remains to elucidate the other biochemical
steps that are required for necrosis execution, either down-
stream of PGAM5 and Drp1 or in parallel.(C) The cells were treated as indicated for 6 hr.WCE and SDS-supwere harvested
(D) The cells were treated as indicated for 6 hr. Whole-cell extract was subjected
performed with an anti-Drp1 antibody. The relative intensity was labeled under e
(E) The cells were treated as indicated for 6 hr. Whole-cell lysates were subject
analysis using an antibody against Drp1.
(F) The indicated cells were pretreated with different concentrations of mdivi-1 fo
(G) The indicated cells were transfected with three rounds of siRNAs against Luc,
are represented as the mean ± STDEV of duplicates. Western blotting was perfo
(H) Working model. Red region represents the mitochondrial SDS-soluble domai
See the text for details. Supported by Figure S4.
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Reagents
TNF-a and the Smacmimetic were prepared as previously described (He et al.,
2009). Z-VAD-fmk was from Bachem, and Necrostatin-1 from Alexis Biochem-
icals. l-Phosphatase was from NEB. Mdivi-1, A23187, Anti-Flag-M2-agarose
(A1205), anti-HA-agarose (A2095), and anti-c-Myc-agarose (A7470) were from
Sigma. The following antibodies were used: anti-Flag (Sigma, A8592), anti-c-
Myc (Santa Cruz, sc-47694), anti-HA (Santa Cruz, sc-805), anti-RIP1 (BD
Biosciences, 610458), anti-Tom20 (Santa Cruz, sc-11415), anti-MLKL (Sigma,
M6697), anti-Drp1 (Santa Cruz, sc-101270 and sc-32989; Abcam, ab56788),
and anti-phospho-Drp1 (ser637) (Cell Signaling, 4867). Anti-PGAM5 polyclonal
antibody was generated against a fragment encoding the amino acid residues
89–289 of PGAM5L.
siRNA Transfection and CellTiter-Glo Assay
To improve the knockdown efficiency, three rounds of siRNA transfection were
performed for mitochondrial genes. On day 0, cells were split into a 6-well
plate at a density of 40,000 cells/well and transfected with 200 pmol siRNA
in each well. On day 2, another 200 pmol siRNA was transfected. On day 4,
the cells were split into a 96-well plate at a density of 2,000 cells/well and
transfected with 10 pmol siRNA in each well. On day 6, the cells were treated
as indicated. On day 7, the CellTiter-Glo assay was performed according
to the manufacturer’s instructions (Promega, G7570). For other treatments,
4,000 cells were plated into each well of a 96-well plate. Luminescence was
measured using a ‘‘Synergy HT’’ machine from Biotek. Vehicle (DMSO) treat-
ment was assigned as 100 percent, and the experimental treatment was
divided by the vehicle treatment to calculate the percentage of cell survival.
For all of the CellTiter-Glo assays, the mean ± STDEV of duplicates were
presented.
Stable Cell Lines
Stable cell lines expressing the Tet repressor (TetR) were selected with
10 mg/ml Blasticidin after being transfected with the pcDNA6/TR plasmid
from Invitrogen. HeLa-TetR cells were transfected with a pCDNA3 plasmid
encoding HA-3xFlag-Rip3 and selected with 1 mg/ml G418 to establish the
HeLa/TO-Rip3 cell line. The same strategy was used to establish the HeLa/
TO-Rip3-K50A cell line. Stable lines with inducible shRNA expression were
established as previously described (Zhong et al., 2005). Briefly, multiple
copies of shRNA under the control of the H1 promoter were cloned into the
pSuperior.puro vector (Oligoengine). The shRNA expressing plasmids were
then transfected into the TetR cells and selected with 0.5 mg/ml puromycin.
Rescue cell lines were established in the shRNA expressing cells using
scramble expression constructs that were resistant to the shRNAs and con-
tained hygromycin-resistant cassettes.
Immunoprecipitation
Cell extract was mixed with anti-Flag, anti-Myc, or anti-HA agarose beads in
a ratio of 1 mg of extract per 30 ml of agarose at 4C overnight. The beads
were then pelleted at 2,500 3 g for 3 min and washed with lysis buffer five
times. The beads were subjected to elution with 5 vol of 0.5 mg/ml peptide
for 4 hr or directly boiled in 1 3 SDS loading buffer.as in Figure 3F and analyzed bywestern blotting using the indicated antibodies.
to immunoprecipitation with anti-Drp1-p637 antibody. Western blotting was
ach lane.
ed to a nonreducing SDS-PAGE gel separation followed by western blotting
r 1 hr. TSZ were added for additional 14 hr and cell viability was measured.
or RIP1, or Drp1. Cell viability was measured after 14 hr of TSZ treatment. Data
rmed to assay the knockdown efficiency.
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Figure 7. PGAM5 and Drp1 Are Required for ROS and Calcium Overload-Induced Necrosis
(A) HT-29 cells were treated with 100 mM of t-butyl-hydroperoxide (TBH) for 24 hr. Immunostaining was performed using an anti-Tom20 antibody.
(B) HT-29 cells were pretreated for 1 hr with Z-VAD or 5 mM N-acetyl-cysteine (NAC). The cells were then treated with 100 mM of TBH for 24 hr, and cell viability
was determined.
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Flag-HA Tandem Pull-Down and Mass Spectrometry
In total, 15 mg of P15 extract was incubated overnight with 300 ml of anti-Flag
M2-agarose. After five washes with lysis buffer, the beads were eluted twice
with 1 ml of lysis buffer containing 0.5 mg/ml 3xFlag peptide for 4 hr. The
combined elution was incubated overnight with 50 ml anti-HA agarose. After
five washes with lysis buffer, the beads were eluted with 200 ml of lysis buffer
containing 0.5 mg/ml HA peptide for 4 hr. A total of 15 ml of 4 3 SDS loading
buffer was added to the final elution, and the mixture was boiled down to
60 ml and loaded into a 4%–12% gradient gel (Invitrogen, NP0321). All of the
procedures were performed at 4C unless otherwise stated. Silver staining
was performed according to the manufacturer’s instructions (SilverQuest
silver staining kit, Invitrogen, LC6070).Kinase Assay
Anti-Flag immunoprecipitation was performed as described above. After three
washes with the kinase buffer (50 mM Tris [pH 7.5], 10 mM MgCl2, 50 mM
NaCl, 0.1% BSA, 100 mM ATP, and 1 mM DTT), the beads were incubated
with 2 mCi of g-32P-ATP at 30C for 1 hr with or without recombinant His-
tagged PGAM5L. The reactions were then loaded onto a 12% SDS-PGAE
gel and subject to autoradiography analysis. All of the buffers included
a protease inhibitor cocktail from Roche, #11873580001, and phosphatase
inhibitor mix (20 mM glycerol b-phosphate, 10 mM NaF, 0.5 mM sodium
orthovanadate, and 5 mM sodium pyrophosphate).Phosphatase Assay
Anti-Flag immunoprecipitation and kinase reactions with recombinant His-
tagged PGAM5L were performed as described above without g-32P-ATP
and the phosphatase inhibitor mix. The recombinant His-tagged PGAM5L
was purified using Ni-NTA beads (QIAGEN). After three washes with phospha-
tase buffer (50 mM imidazole [pH 7.2], 0.2 mM EGTA, 0.02% 2-mecaptoetha-
nol, and 0.1 mg/ml BSA), the Ni-NTA beads were incubated with 100 mM of
a phospho-Thr peptide (RRApTVA, Promega) at 30C for 1 hr. The released
free phosphate was quantified using the Phosphatase Assay System from
Promega (V2460).GTPase Assay
A total of 1 mg of whole-cell extract was immunoprecipitated overnight with
20 mg of anti-Drp1 antibody (Santa Cruz, sc-32989) and 100 ml of protein
A/G-agarose (Santa Cruz). After three washes with lysis buffer and three
washes with GTPase buffer (50 mM Tris [pH 7.5], 2.5 mM MgCl2, and 0.02%
2-mercaptoethanol), the beads were incubated with 0.5 mM GTP at 30C for
1 hr. The released free phosphate was quantified using the PiColorLock
Gold kit from Innova Biosciences.
For in vitro PGAM5L treatment, immunopurified Drp1 was incubated with
300 ng of recombinant PGAM5L in phosphatase buffer at 30C for 1 hr. After
three washes with GTPase buffer, the beads were incubated with 0.5 mM
GTP at 30C for 1 hr. The released free phosphate was quantified using the
PiColorLock Gold kit.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and can be found with this
article online at doi:10.1016/j.cell.2011.11.030.(C) Stable cell lines derived fromHT-29 cells that express shRNA against RIP3 or P
determined.
(D) The cells as in (C) were treated with 5 mM H2O2 for 1 hr and replaced with fres
(E) The cells as in (C) were treated with 30 mM of calcium ionophore A23187 and
(F) HT-29 cells were transfected with three rounds of indicated siRNAs. Cell viab
(G) The cells were prepared as in (F). Cell viability was determined as in (D).
(H) The cells were prepared as in (F). Cell viability was determined after 24 hr tre
Data are represented as the mean ± STDEV of duplicates. Supported by Figure
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